TricValve Pop-Out: Management of Transcatheter Caval Valve Migration

Tricuspid valve disease, particularly tricuspid regurgitation (TR), has been a “neglected valvulopathy” for many years. In patients with left heart pathologies, chronic pressure overload on the right ventricle causes functional TR and is associated with a poor prognosis.1 Treatment of severe symptomatic TR has usually been restricted to diuretics and mostly remained ineffective.2 Moreover, patients undergoing surgical repair of isolated tricuspid valve disease have the highest mortality of all valves, due to advanced right ventricular dysfunction and coexisting comorbidities.3 Thus, transcatheter tricuspid valve therapy (TTVT) has emerged as a novel strategy for patients with high or prohibitive surgical risk. In this case, we performed bicaval valve implantation using TricValve to reduce caval backflow on a symptomatic patient with severe functional TR and successfully managed device migration complications.